Sanofi Says US FDA Approves Subcutaneous Sarclisa for Multiple Myeloma
() -- Sanofi (SNY) said Friday the US Food and Drug Administration has approved subcutaneous Sarclisa Escena combined with standard-of-care regimens to treat multiple myeloma across all existing indications for the intravenous formulation. Sarclisa may now be delivered via both manual subcutaneous injection and the Cir